Trial Profile
Randomised, Double-blind, Placebo-controlled, Phase I Dose- Escalation Study of Two Doses GHB04L1 in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Influenza virus delta-NS1 vaccine (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; First in man
- Sponsors AVIR Green Hills Biotechnology
- 30 May 2019 Results assessing safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine published in the Vaccine